Citadel Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-444
| Closed | -$6.56K | – | 15883 |
|
|
2024
Q1 | $6.56K | Buy |
+444
| New | +$6.24K | ﹤0.01% | 13658 |
|
|
2023
Q4 | – | Sell |
-3,398
| Closed | -$42.9K | – | 15763 |
|
|
2023
Q3 | $41.9K | Sell |
3,398
-299
| -8% | -$3.62K | ﹤0.01% | 11954 |
|
|
2023
Q2 | $45.5K | Sell |
3,697
-4,794
| -56% | -$59.9K | ﹤0.01% | 11914 |
|
|
2023
Q1 | $104K | Buy |
+8,491
| New | +$99.8K | ﹤0.01% | 11198 |
|
|
2022
Q4 | – | Sell |
-13,718
| Closed | -$113K | – | 16098 |
|
|
2022
Q3 | $51K | Sell |
13,718
-2,493
| -15% | -$11.5K | ﹤0.01% | 11622 |
|
|
2022
Q2 | $97K | Buy |
+16,211
| New | +$91.5K | ﹤0.01% | 11442 |
|
|
2021
Q4 | – | Sell |
-10,622
| Closed | -$51K | – | 15563 |
|
|
2021
Q3 | $51K | Sell |
10,622
-8,530
| -45% | -$44.5K | ﹤0.01% | 13365 |
|
|
2021
Q2 | $122K | Sell |
19,152
-1,592
| -8% | -$10.5K | ﹤0.01% | 12732 |
|
|
2021
Q1 | $130K | Sell |
20,744
-1,199
| -5% | -$8.57K | ﹤0.01% | 12208 |
|
|
2020
Q4 | $151K | Buy |
+21,943
| New | +$108K | ﹤0.01% | 9940 |
|
|
2020
Q1 | – | Sell |
-10,042
| Closed | -$29.4K | – | 10627 |
|
|
2019
Q4 | $31K | Sell |
10,042
-3,587
| -26% | -$14.4K | ﹤0.01% | 8863 |
|
|
2019
Q3 | $62K | Sell |
13,629
-3,477
| -20% | -$17.4K | ﹤0.01% | 8651 |
|
|
2019
Q2 | $82K | Buy |
+17,106
| New | +$81K | ﹤0.01% | 8593 |
|
|
2019
Q1 | – | Sell |
-21,571
| Closed | -$65K | – | 10370 |
|
|
2018
Q4 | $65K | Sell |
21,571
-1,177
| -5% | -$4.08K | ﹤0.01% | 8416 |
|
|
2018
Q3 | $96K | Sell |
22,748
-9,847
| -30% | -$41.5K | ﹤0.01% | 8592 |
|
|
2018
Q2 | $126K | Buy |
+32,595
| New | +$216K | ﹤0.01% | 8141 |
|
|
2018
Q1 | – | Sell |
-14,929
| Closed | -$120K | – | 9227 |
|
|
2017
Q4 | $120K | Sell |
14,929
-1,026
| -6% | -$9.57K | ﹤0.01% | 7366 |
|
|
2017
Q3 | $183K | Buy |
15,955
+3,131
| +24% | +$32.9K | ﹤0.01% | 6765 |
|
|
2017
Q2 | $125K | Sell |
12,824
-23,131
| -64% | -$472K | ﹤0.01% | 6828 |
|
|
2017
Q1 | $871K | Buy |
35,955
+9,569
| +36% | +$239K | ﹤0.01% | 4206 |
|
|
2016
Q4 | $847K | Sell |
26,386
-7,503
| -22% | -$320K | ﹤0.01% | 4087 |
|
|
2016
Q3 | $1.69M | Buy |
33,889
+4,284
| +14% | +$178K | ﹤0.01% | 3175 |
|
|
2016
Q2 | $1.25M | Buy |
29,605
+15,021
| +103% | +$818K | ﹤0.01% | 3289 |
|
|
2016
Q1 | $960K | Buy |
+14,584
| New | +$761K | ﹤0.01% | 3544 |
|
|
2015
Q4 | – | Sell |
-79,438
| Closed | -$5.59M | – | 9529 |
|
|
2015
Q3 | $5.32M | Buy |
+79,438
| New | +$6.48M | 0.01% | 1886 |
|
|
2015
Q1 | – | Sell |
-6,228
| Closed | -$530K | – | 9068 |
|
|
2014
Q4 | $553K | Sell |
6,228
-14,019
| -69% | -$1.02M | ﹤0.01% | 4594 |
|
|
2014
Q3 | $1.4M | Buy |
20,247
+18,937
| +1,446% | +$1.01M | ﹤0.01% | 3282 |
|
|
2014
Q2 | $75K | Buy |
+1,310
| New | +$66.5K | ﹤0.01% | 6461 |
|
|
2014
Q1 | – | Sell |
-729
| Closed | -$31.2K | – | 8154 |
|
|
2013
Q4 | $31K | Buy |
729
+508
| +230% | +$14.7K | ﹤0.01% | 6271 |
|
|
2013
Q3 | $7K | Buy |
+221
| New | +$7.73K | ﹤0.01% | 6538 |
|
Other funds holding MACK
RA
JC
Citadel Advisors's MACK Position: Q2 2024 in Review
Citadel Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 444 shares — an estimated $6.56K sold.
Citadel Advisors first reported a position in MACK in Q3 2013 and held it in 30 quarters. The position peaked at $5.32M in Q3 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Citadel Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 444 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $6.56K.
- Citadel Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $5.32M in Q3 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.